MedPageToday -- ORLANDO -- The oral factor Xa inhibitor rivaroxaban (Xarelto) reduced the risk of recurrent venous thromboembolism (VTE) with no increase in bleeding, according to results of two large clinical trials reported here.
MedPageToday -- ORLANDO -- The oral factor Xa inhibitor rivaroxaban (Xarelto) reduced the risk of recurrent venous thromboembolism (VTE) with no increase in bleeding, according to results of two large clinical trials reported here.